ce
chief
medic
offi
cer
northern
health
region
british
columbia
vancouv
british
columbia
canada
patient
day
die
friend
healthcar
worker
contact
day
death
rest
healthcar
worker
contact
patient
day
die
knowledg
fi
rst
import
case
tenth
case
hp
report
british
columbia
canada
sinc
bc
annual
summari
report
diseas
avail
wwwbccdcorgcontentphp
six
case
fatal
case
except
describ
local
acquir
sin
nombr
infect
sin
nombr
viru
endem
peromyscu
maniculatu
deer
mice
popul
british
columbia
worldwid
import
case
hp
unusu
although
hp
report
countri
close
geograph
proxim
travel
diseaseendem
area
fortun
none
person
expos
patient
report
symptom
consist
hp
incub
period
none
test
seroconvert
seropreval
survey
chile
among
healthcar
worker
contact
patient
hp
caus
and
viru
show
preval
report
argentina
show
case
due
secondari
transmiss
occur
mostli
nonhealthcar
worker
prolong
close
contact
prodrom
period
conclus
describ
import
case
fatal
hp
due
andeslik
hantaviru
evid
secondari
transmiss
editor
human
bocaviru
hbov
increasingli
recogn
caus
respiratori
infect
worldwid
children
infant
appear
risk
although
hbov
role
immunocompromis
patient
remain
unclear
report
child
dissemin
hbov
infect
hematopoiet
stem
cell
transplant
hsct
hbov
dna
detect
high
level
nasopharyng
aspir
npa
blood
stool
sampl
boy
dyskeratosi
congenita
brought
treatment
hospit
due
sever
persist
cytopenia
allogen
hsct
perform
august
condit
total
bodi
irradi
cgi
day
hsct
surgeri
fl
udarabin
day
antithymocyt
globulin
day
cyclophosphamid
day
receiv
nucleat
bone
marrow
cellskg
bodi
weight
human
leukocyt
antigen
match
unrel
donor
graftversushost
diseas
gvhd
prophylaxi
consist
short
cours
methotrex
cyclosporin
neutrophil
platelet
engraft
occur
day
surgeri
respect
despit
preand
posthsct
antiinfect
prophylaxi
cotrimoxazol
colistin
acyclovir
fl
uconazol
enterobact
cloaca
sepsi
diagnos
day
meropenem
treatment
blood
cultur
remain
neg
day
fever
reoccur
elev
creactiv
protein
valu
mgl
reduc
gener
health
note
bacteri
pathogen
isol
period
patient
receiv
antimicrobi
drug
therapi
meropenem
tobramycin
vancomycin
amphotericin
b
day
bodi
temperatur
peak
cough
dyspnea
without
wheez
develop
chest
radiograph
result
suggest
pneumonia
perihilar
infi
ltrate
reduc
oxygen
satur
po
record
transcutan
oxygen
supplement
maximum
lmin
start
face
mask
onlin
appendix
figur
avail
wwwcdcgoveid
npa
sampl
investig
multiplex
pcr
result
provid
w
pupp
j
weigl
wwwpidarinet
neg
adenoviru
respiratori
syncyti
viru
human
metapneumoviru
parainfl
uenza
virus
infl
uenza
virus
b
coronaviru
reoviru
enteroviru
clamydia
pneumonia
mycoplasma
pneumonia
bordetella
pertussi
b
parapertussi
legionella
pneumophila
posit
rhinoviru
rna
retrospect
npa
sampl
reanalyz
hbov
dna
realtim
pcr
show
viral
load
copiesml
onlin
appendix
figur
specifi
citi
confi
rmed
sequenc
day
patient
gener
health
improv
chest
radiograph
result
return
normal
neutrophil
engraft
day
addit
erythromycin
antimicrobi
drug
regimen
bodi
temperatur
decreas
oxygen
supplement
discontinu
howev
rhiniti
cough
lowgrad
fever
persist
day
onlin
appendix
figur
hbov
dna
detect
npa
day
copiesml
respect
onlin
appendix
figur
npa
sampl
day
still
rhinoviru
posit
concurr
increas
hbov
load
npa
cytomegaloviru
cmv
reactiv
fi
rst
diagnos
pcr
day
peak
copiesml
whole
blood
day
despit
gancyclovir
therapi
switch
foscarnet
led
temporari
control
cmv
replic
onlin
appendix
figur
addit
day
acut
gvhd
grade
skin
manifest
develop
treatment
steroid
day
led
complet
resolut
hbov
infect
patient
restrict
respiratori
tract
diarrheic
stool
sampl
obtain
day
resolut
respiratori
symptom
day
show
substanti
hbov
dna
copiesmg
respect
onlin
appendix
figur
test
rotaviru
adenoviru
antigen
neg
bacteri
pathogen
isol
moreov
hbov
dna
detect
lower
level
copiesml
edta
plasma
sampl
taken
day
subsequ
plasma
day
npa
day
stool
day
sampl
neg
hbov
dna
howev
abil
hbov
caus
persist
infect
member
parvovirina
subfamili
exclud
futur
investig
need
address
hypothesi
report
dissemin
hbov
infect
immunocompromis
patient
whether
clinic
cours
case
sever
prolong
would
hbov
infect
nonhsct
children
remain
unknown
due
lack
longterm
observ
immunocompet
children
dramat
increas
hbov
load
npa
viral
dissemin
like
result
progress
impair
cellular
immun
indic
simultan
cmv
reactiv
moreov
increas
viral
load
might
also
consequ
steroid
addit
immunosuppress
therapi
control
gvhd
contribut
hbov
respiratori
diseas
remain
ambigu
npa
sampl
also
rhinoviru
posit
addit
studi
requir
investig
pathogen
role
hbov
doubl
multipl
infect
associ
hbov
patient
continu
diarrhea
accord
previou
studi
prolong
fecal
shed
import
implic
isol
measur
transplant
unit
studi
immunocompromis
patient
requir
evalu
spectrum
patholog
caus
emerg
viru
editor
isoniazid
fi
rstline
drug
treatment
tuberculosi
use
includ
prevent
well
cure
isoniazid
usual
well
toler
although
common
side
effect
includ
gastrointestin
discomfort
rash
allergi
hepat
peripher
neuropathi
hematolog
disord
eosinophilia
thrombocytopenia
autoimmun
hemolyt
anemia
rare
report
pure
red
cell
aplasia
prca
uncommon
disord
adult
prca
occur
secondari
drug
exposur
patient
drug
implic
report
involv
isoniazid
publish
report
case
isoniazidinduc
prca
woman
sought
care
public
assist
hospit
pari
report
asthenia
breathless
decreas
appetit
week
nodeneg
local
gastric
adenocarcinoma
year
earlier
treat
partial
gastrectomi
pulmonari
tuberculosi
treat
partial
pneumonectomi
result
pleuropulmonari
tuberculosi
relaps
diagnos
week
earlier
receiv
antitubercul
treatment
rifampin
mgday
isoniazid
mgday
ethambutol
mgday
pyrazinamid
mgday
receiv
concomit
medic
initi
physic
examin
show
noth
abnorm
laboratori
analysi
show
hemoglobin
g
dl
leukocyt
thrombocyt
count
within
normal
limit
reticulocyt
zero
schizocyt
test
result
liver
renal
function
serum
folat
vitamin
level
lactic
dehydrogenas
level
creactiv
protein
serum
protein
electrophoresi
direct
indirect
coomb
test
antinuclear
antibodi
test
within
normal
limit
viral
serolog
test
result
hiv
hepat
b
viru
hepat
c
viru
parvoviru
upper
lower
digest
tract
endoscop
examin
carcinoembryon
antigen
show
abnorm
lessen
likelihood
tumor
relaps
bone
marrow
aspir
sternum
show
hypocellular
marrow
complet
absenc
erythroid
seri
normal
myeloid
seri
megakaryocyt
marrow
fi
nding
consist
prca
view
previou
report
isoniazidinduc
prca
suspect
drug
respons
case
isoniazid
withdrawn
antitubercul
drug
continu
patient
hemoglobin
level
rose
gdl
reticulocyt
count
day
blood
transfus
requir
druginduc
prca
rare
blood
disord
adult
alreadi
report
isoniazidtr
patient
patient
caus
anemia
eg
druginduc
hemolyt
anemia
digest
malign
viral
caus
known
date
hematolog
malign
autoimmun
disord
exclud
favor
outcom
isoniazid
withdraw
increas
likelihood
isoniazid
caus
although
rechalleng
isoniazid
could
confi
rmed
isoniazid
caus
ethic
option
hazard
advers
effect
exact
mechan
isoniazidinduc
prca
remain
unclear
demonstr
antibodi
react
nucleat
red
blood
cell
case
suggest
induct
autoimmun
hypothesi
support
previous
report
case
prca
relaps
occur
treatment
isoniazid
resum
intrins
imput
isoniazid
also
reli
lack
doseeffect
relationship
delay
introduct
opinion
express
author
contribut
journal
necessarili
refl
ect
opinion
center
diseas
control
prevent
institut
author
affi
liat
